In this review article, published in the journal Immunotherapy, the authors explore immunotherapy for neuroblastoma from therapeutic backbone to the latest discoveries.
A combination of CBL0137 and panobinostat has been demonstrated to effectively treat neuroblastoma in mice. This combination therapy has the potential to lead the fight against this aggressive childhood cancer.
This week, our industry report covers neuroblastoma, DUB inhibitors for neurodegenerative diseases and pediatric multiple sclerosis.
In partnership with The Brain Tumour Charity, the Cancer Research UK Brain Tumour Awards hope to tackle six major themes in brain tumor research.
From novel biomarkers, to the potential use of the Zika virus as a tumor treatment, read our round-up of the biggest neuro-oncology news from the last year as we mark World Cancer Day.
A new assay test for five cancer-associated genes with the goal of aiding prediction of neuroblastoma in children has been reported.
Investigators hope that their findings will assist in the development of targeted treatments for pediatric brain cancers.
The European Commission has approved dinutuximab beta for the treatment of high-risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy for these patients in Europe.
A reduction in tumor size of up to 80% has been observed in a current Phase II clinical trial utilizing a newly engineered monoclonal antibody in combination with chemotherapy to treat young, high-risk, neuroblastoma patients.
The results of a Phase III trial have indicated that the addition of a second autologous stem cell transplant to therapy for children with neuroblastoma could improve survival.